KeifeRx vs Sitryx
KeifeRx
KeifeRx is a biopharmaceutical company finding disease-modifying treatments for neurodegenerative diseases. #HoyaSaxa
7 employees · est. 2019 · Mclean, United States
Sitryx
Harnessing the power of cell metabolism to develop groundbreaking disease-modifying therapies
48 employees · est. 2018 · Oxford, United Kingdom
Sitryx is the older company (2019 vs 2018); Sitryx is the larger of the two.
5 signals in the last 90 days
Side-by-Side Comparison
| Metric | KeifeRx | Sitryx |
|---|---|---|
| Founded | ||
| Founded | 2019 | 2018 older |
| Headquarters | ||
| Headquarters | Mclean, United States | Oxford, United Kingdom |
| Employees | ||
| Employees | 7 | 48 larger |
| Industry | ||
| Industry | Biopharma, Biotechnology, Pharmaceutical | Biotechnology, Health Care, Pharmaceutical |
| Funding Stage | ||
| Funding Stage | Series A | Series A |
| Total Funding | ||
| Total Funding | $6.00M | $79.00M |
| Funding Rounds | ||
| Funding Rounds | 1 | 3 |
| Services | ||
| Services | development of kinase inhibitors, clinical trials for neurodegenerative disease treatments, collaborative research for drug development | Developing novel oral therapies, Restoring immune balance, Disease remission through precision immunology |
| Target Customers | ||
| Target Customers | dementia patients, patients with neurodegenerative diseases, healthcare providers in neurology, clinical researchers | Patients with autoimmune and inflammatory diseases, Global biopharmaceutical companies seeking strategic partnerships |
| Taxonomy | ||
| Taxonomy | BiopharmaceuticalClinical-stageNeurodegenerative DiseasesDisease-modifying TreatmentsTyrosine Kinase InhibitorsLow Dose Therapy +8 | BiopharmaceuticalCell MetabolismDisease-modifying TherapeuticsImmuno-oncologyImmuno-inflammationImmunometabolism +9 |
| Website | ||
| Website | keiferx.com | sitryx.com |
About KeifeRx
KeifeRx, founded in 2019, is an emerging biopharmaceutical company headquartered in the United States. The company specializes in developing innovative treatments for neurodegenerative and immune diseases using novel tyrosine kinase inhibitors (TKIs). By focusing on low-dose, orally delivered soluti...
About Sitryx
Sitryx is a dynamic player in the biopharmaceutical sector, leveraging the innovative capabilities of cell metabolism to pioneer novel, disease-modifying therapies focused on immuno-oncology and immuno-inflammation. Founded in 2018, the company operates from its headquarters in Oxford, UK. The core...
Also comparing in this category
Comparing more than these two?
Get KeifeRx, Sitryx and up to nine more competitors side by side in one PDF: team, funding, traffic and every dated move of the last six months. Every company is re-checked on the day you order.
How does KeifeRx compare?
A PDF of KeifeRx and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Rival Readout
Comparing competitors? We do this properly.
10 rivals, 90 days of dated moves in 7 business days: a ranked list of what matters, each with its source, ending in a 60-minute readout with your team.
Frequently Asked Questions
Compare KeifeRx with someone else
Start typing a company name or domain.
Related Comparisons
Compiled from the BounceWatch company index. We last looked at KeifeRx on 11 Mar 2026, and Sitryx on 6 May 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.